Lenox Wealth Advisors Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 1.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,822 shares of the biopharmaceutical company’s stock after selling 302 shares during the period. Pfizer accounts for approximately 0.2% of Lenox Wealth Advisors Inc.’s portfolio, making the stock its 21st largest position. Lenox Wealth Advisors Inc.’s holdings in Pfizer were worth $570,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in PFE. Nelson Roberts Investment Advisors LLC boosted its stake in Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 189 shares during the last quarter. Stelac Advisory Services LLC purchased a new stake in Pfizer during the second quarter worth approximately $110,000. Tuttle Tactical Management LLC purchased a new stake in Pfizer during the second quarter worth approximately $117,000. Catamount Wealth Management boosted its stake in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares during the last quarter. Finally, Delphi Private Advisors LLC boosted its stake in Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 47 shares during the last quarter. Hedge funds and other institutional investors own 69.48% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded up 0.86% during trading on Friday, hitting $31.69. 10,452,948 shares of the stock traded hands. Pfizer Inc. has a 52-week low of $28.25 and a 52-week high of $37.39. The stock has a market cap of $192.31 billion, a P/E ratio of 31.82 and a beta of 0.90. The company’s 50 day moving average price is $32.01 and its 200-day moving average price is $34.15.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $0.61 EPS for the quarter, missing the Zacks’ consensus estimate of $0.62 by $0.01. The firm had revenue of $13.05 billion for the quarter, compared to analysts’ expectations of $13.05 billion. Pfizer had a return on equity of 23.68% and a net margin of 13.09%. The firm’s quarterly revenue was up 7.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 EPS. Equities research analysts forecast that Pfizer Inc. will post $2.41 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.79%. Pfizer’s payout ratio is currently 106.20%.
A number of equities research analysts recently commented on the stock. Vetr raised shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.42 target price for the company in a research report on Monday, October 17th. Sanford C. Bernstein reissued an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, November 2nd. Bank of America Corp. reaffirmed a “buy” rating and issued a $36.00 price target (down previously from $40.00) on shares of Pfizer in a report on Monday, November 7th. Finally, Atlantic Securities set a $35.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Thursday, November 3rd. Thirteen investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $37.73.
In other news, insider Anthony J. Maddaluna sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $33.00, for a total transaction of $330,000.00. Following the transaction, the insider now directly owns 112,087 shares of the company’s stock, valued at approximately $3,698,871. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Albert Bourla sold 18,390 shares of the company’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $30.05, for a total transaction of $552,619.50. Following the transaction, the insider now directly owns 149,199 shares in the company, valued at $4,483,429.95. The disclosure for this sale can be found here. Company insiders own 0.07% of the company’s stock.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.